Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Am Osteopath Assoc ; 110(9 Suppl 8): S16-26, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20926739

ABSTRACT

There is neither proven effective prevention for Alzheimer disease nor a cure for patients with this disorder. Nevertheless, a spectrum of biopsychosocial therapeutic measures is available for slowing progression of the illness and enhancing quality of life for patients. These measures include a range of educational, psychological, social, and behavioral interventions that remain fundamental to effective care. Also available are a number of pharmacologic treatments, including prescription medications approved by the US Food and Drug Administration for Alzheimer disease, "off-label" uses of medications to manage target symptoms, and controversial complementary therapies. Physicians must make the earliest possible diagnosis to use these treatments most effectively. Physicians' goals should be to educate patients and their caregivers, to plan long-term care options, to maximally manage concurrent illnesses, to slow and ameliorate the most disabling symptoms, and to preserve effective functioning for as long as possible. The authors review the various current treatments for patients with Alzheimer disease.


Subject(s)
Alzheimer Disease/drug therapy , Aggression , Alzheimer Disease/psychology , Alzheimer Disease/therapy , Behavior Therapy , Cholinesterase Inhibitors/therapeutic use , Depression/etiology , Excitatory Amino Acid Antagonists/therapeutic use , Galantamine/therapeutic use , Health Status , Humans , Memantine/therapeutic use , Neuroprotective Agents/therapeutic use , Parasympathomimetics/therapeutic use , Phenylcarbamates/therapeutic use , Psychomotor Agitation/etiology , Psychotherapy , Psychotic Disorders/etiology , Rivastigmine , Time Factors , United States , United States Food and Drug Administration
3.
Gen Hosp Psychiatry ; 25(2): 63-73, 2003.
Article in English | MEDLINE | ID: mdl-12676418

ABSTRACT

Patients with medically unexplained symptoms (MUS) often are a source of frustration for clinicians, and despite high quality biomedical attention and frequent diagnostic tests, they have poor health outcomes. Following upon progress in depression treatment approaches, we developed a multidimensional treatment protocol for deployment by primary care personnel. This multi-faceted intervention for MUS patients emphasized cognitive-behavioral principles, the provider-patient relationship, pharmacological management, and treating comorbid medical diseases. We deployed it in an HMO using nurse practitioners (NP) to deliver the intervention to 101 patients, while 102 controls continued to receive medical care from their usual primary care physician. Successful deployment of the intervention required training the NPs, continuing support for the NPs in their management of this difficult population, and establishing strong communication links with the HMO. This paper addresses the practical considerations of using primary care personnel to implement a complex intervention in primary care, and it includes a discussion of special challenges encountered as well as solutions developed to overcome them.


Subject(s)
Depressive Disorder/therapy , Health Maintenance Organizations/standards , Mental Health Services/standards , Nurse Practitioners/statistics & numerical data , Primary Health Care/standards , Somatoform Disorders/diagnosis , Adolescent , Adult , Clinical Protocols , Cognitive Behavioral Therapy/methods , Depressive Disorder/economics , Female , Follow-Up Studies , Humans , Male , Middle Aged , Nurse Practitioners/education , Nurse Practitioners/standards , Personnel Selection , Professional-Patient Relations , Quality Assurance, Health Care , United States , Workforce
SELECTION OF CITATIONS
SEARCH DETAIL
...